Skip to main content

Sigma-Aldrich Buys Stake in Genospectra as Firms Plan to Co-Develop Cell-Based Assay Tools ...

NEW YORK, Feb. 10 (GenomeWeb News) - Sigma-Aldrich has acquired a minority equity stake in Genospectra and has obtained access to various Genospectra technologies as part of a broad R&D alliance, the companies said today.

 

As part of the deal, the companies said they plan to develop new technology and products in the area of cell-based assays. In particular, the companies aim to develop live-cell biosensor assay reagents that can provide real-time data on the location and activity of proteins in living cells.

 

Other terms of the alliance call for Sigma to gain access to Genospectra's QuantiGene gene expression-profiling assay and its nano-particle system for delivery of siRNA and other biomolecules to cells, called its inducible siRNA technologies.

 

Financial details of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.